Date of Birth*

Fund Name

Retirement Date Range

1937 and before

or missing/invalid date of birth

Fidelity Freedom K® Income Fund

2002 and before

1938-1942

Fidelity Freedom K® 2005 Fund

2003-2007

1943-1947

Fidelity Freedom K® 2010 Fund

2008-2012

1948-1952

Fidelity Freedom K® 2015 Fund

2013-2017

1953-1957

Fidelity Freedom K® 2020 Fund

2018-2022

1958-1962

Fidelity Freedom K® 2025 Fund

2023-2027

1963-1967

Fidelity Freedom K® 2030 Fund

2028-2032

1968-1972

Fidelity Freedom K® 2035 Fund

2033-2037

1973-1977

Fidelity Freedom K® 2040 Fund

2038-2042

1978-1982

Fidelity Freedom K® 2045 Fund

2043-2047

1983-1987

Fidelity Freedom K® 2050 Fund

2048-2052

1988 and later

Fidelity Freedom K® 2055 Fund

2053 and later

Date

Activity

What it means to you

February 4, 2015 at 4:00 p.m. Eastern time

Last day distributions from the Covance Stock Fund can be taken as In-Kind shares of Covance stock.

·         Distributions from the Covance Stock Fund can no longer be provided as In-Kind shares of Covance stock and will be provided in cash only

February 17, 2015 at 4:00 p.m. Eastern time

The Covance Stock Fund is closed to investment election changes.

·         The Covance Stock Fund is no longer available to new investments elections. All future contributions currently directed to the Covance Stock Fund will be directed to a Fidelity Freedom K® Fund based on your age

Two days prior to the closing of the merger

Blackout Period begins at 4:00 p.m., Eastern time.

Holdings in the Covance Stock Fund are not available for:

·         Exchanges in or out

·         Loans or distributions

On or about February 19, 2015

·                  Each share of Covance stock in the Covance Stock Fund is converted

·         Once proceeds are received, they will be invested temporarily in

into 0.2686 of LabCorp stock per equivalent share of Covance Stock Fund held plus $75.76 in cash.

·         The LabCorp stock and the cash will be invested in the Stock Liquidation Fund.

the Stock Liquidation Fund.

·         Once this reallocation is complete, the blackout period will end.

The week of February 22, 2015

The Stock Liquidation Fund holdings are liquidated.

·         All plan activities are now available

·         Stock Liquidation Fund holdings are transferred to your investment elections on file.

·         If no election is on file or your current investment elections are fully designated to the Covance Stock Fund, Stock Liquidation Fund holdings will be transferred to the Fidelity Freedom K® Fund based on your age.

Cautionary Statement Regarding Forward Looking Statements

This information was provided by Covance, Inc.

This communication contains “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA.  These statements, as they relate to Laboratory Corporation of America Holdings (“LabCorp”) or Covance Inc. (“Covance”), the management of either such company or the proposed transaction between LabCorp and Covance, involve risks and uncertainties that may cause results to differ materially from those set forth in the statements.  These statements are based on current plans, estimates and projections, and therefore, you are cautioned not to place undue reliance on them.  No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.  LabCorp and Covance undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.  Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmaceutical industry, and other legal, regulatory and economic developments.  We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe harbor provisions of the PSLRA.  Actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including, but not limited to, those described in the documents LabCorp and Covance have filed with the U.S. Securities and Exchange Commission (the “SEC”) as well as the possibility that (1) LabCorp and Covance may be unable to obtain stockholder or regulatory approvals required for the proposed transaction or may be required to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals; (2) the length of time necessary to consummate the proposed transaction may be longer than anticipated; (3) problems may arise in successfully integrating the businesses of LabCorp and Covance or such integration may be more difficult, time-consuming or costly than expected; (4) the proposed transaction may involve unexpected costs; (5) the businesses may suffer as a result of uncertainty surrounding the proposed transaction, including difficulties in maintaining relationships with customers or retaining key employees; (6) the parties may be unable to meet expectations regarding the timing, completion and accounting and tax treatments of the transaction; or (7) the industry may be subject to future risks that are described in the “Risk Factors” section of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, the definitive proxy statement/prospectus referred to below and other documents filed from time to time with the SEC by LabCorp and Covance.  Neither LabCorp nor Covance gives any assurance that either LabCorp or Covance will achieve its expectations.

The foregoing list of factors is not exhaustive.  You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of LabCorp and Covance described in the “Risk Factors” section of their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, the definitive proxy statement/prospectus referred to below and other documents filed by either of them from time to time with the SEC.  All forward-looking statements included in this document are based upon information available to LabCorp and Covance on the date hereof, and neither LabCorp nor Covance assumes any obligation to update or revise any such forward-looking statements.

Additional Information and Where to Find It

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this press release in any jurisdiction in contravention of applicable law.  This document relates to a proposed transaction between Covance and LabCorp, and may be deemed to be solicitation material in respect of the proposed transaction.  In connection with the proposed transaction, LabCorp filed a registration statement on Form S-4 with the SEC, which was declared effective by the SEC on January 14, 2015, and LabCorp and Covance filed the definitive proxy statement/prospectus in connection with the proposed transaction on January 16, 2015.  Covance began mailing the definitive proxy statement/prospectus to Covance stockholders on January 20, 2015.  This document is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Covance or LabCorp may file with the SEC or send to stockholders in connection with the proposed transaction. Before making any voting decision, investors and security holders of Covance are urged to read carefully and in their entirety the registration statement, definitive proxy statement/prospectus and all other relevant documents filed or that will be filed by LabCorp or Covance with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction and related matters.

Investors and security holders will be able to obtain free copies of the registration statement, definitive proxy statement/prospectus and all other relevant documents filed or that will be filed by Covance or LabCorp with the SEC through the website maintained by the SEC at www.sec.gov.

In addition, investors and security holders may obtain free copies of the definitive proxy statement/prospectus and other relevant documents filed by Covance with the SEC by accessing Covance’s website at www.covance.com or upon written request to Covance Inc., Office of the Secretary, 210 Carnegie Center, Princeton, New Jersey 08540.  Free copies of the registration statement, definitive proxy statement/prospectus and other relevant documents filed by LabCorp with the SEC are available on LabCorp’s website at www.labcorp.com or upon written request to Laboratory Corporation of America Holdings, Office of the Secretary, 358 South Main Street, Burlington, North Carolina 27215.

Participants in Solicitation

LabCorp, Covance and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Covance’s stockholders in connection with the proposed transaction.  Information regarding Covance’s directors and executive officers is contained in the proxy statement for Covance’s 2014 Annual Meeting of Shareholders, which was filed with the SEC on March 24, 2014.  You can obtain a free copy of this document at the SEC’s website at www.sec.gov or by accessing Covance’s website at www.covance.com.  Information regarding LabCorp’s executive officers and directors is contained in the proxy statement for LabCorp’s 2014 Annual Meeting of Shareholders filed with the SEC on April 4, 2014. You can obtain a free copy of this document at the SEC’s website at www.sec.gov or by accessing LabCorp’s website at www.labcorp.com.  Additional information regarding those persons and other persons who may be deemed participants in the proxy solicitation, including their respective direct and indirect interests in the proposed transaction, by security holdings or otherwise, is contained in the definitive proxy statement/prospectus and other relevant materials filed with the SEC.  You may obtain free copies of these documents as described in the preceding paragraph.